1 Supplementary Figure Legends

2 Supplementary Figure 1

3	Antibodies to common huCoV's in healthy donor sera. Nucleocapsid
4	(A) and Spike antigens (B) from common human coronaviruses (OC43,
5	HKU1, 229E, NL63) or SARS-CoV-2 were conjugated to microspheres and
6	used in the MIA to determine binding with sera from pre-COVID-19 healthy
7	blood donors. Shown is the median fluorescence intensity of total bound
8	antibodies detected with PE-anti-human lg, along with the 3 SD and 6 SD
9	cutoff values determined for SARS-CoV-2 (used in the clinical NYS CoV
10	MIA).
11	
12	Supplementary Figure 2
13	Relative binding to SARS spike antigens in individual COVID-19 sera.
14	The full spike antigens from SARS-CoV-1 (<i>circles</i>) or SARS-CoV-2
15	(<i>squares</i>), and the SARS CoV-2 spike components: RBD (<i>upward</i>
16	triangles), S1 (downward triangles), and S2 (diamonds), were conjugated
17	to microspheres and used in the MIA to determine binding of total antibodies
18	in sera from COVID-19 convalescent individuals. Results are expressed as
19	index values relative to cutoff MFI's plus 3 SD, determined for each
20	individual antigen. Shown are results from 8 individual patients (part of the
21	specimens used to determine values in Figure 4B)

1

22 Supplementary Figure 3

23	Production of different antibody classes reactive with SARS-CoV-2
24	target antigens. Serum specimens from individuals with SARS-CoV-2
25	infections, confirmed using RT-PCR, and reported symptom onset dates,
26	were assessed for total antibody (Ig), IgM, IgG, and IgA antibodies to
27	different SARS-CoV-2 target antigens (Nucleocapsid, full spike, and
28	separate spike components (RBD, S1 subunit, S2 subunit). Shown are
29	individual index values for each class to the individual target antigens.

30

31 Supplementary Figure 4

Production of different IgG subclasses reactive with SARS-CoV-2 32 target antigens in the MIA. Serum specimens from individuals with SARS-33 34 CoV-2 infections, confirmed using RT-PCR, and reported symptom onset dates were assessed for IgG1, IgG2, IgG3, and IgG4 antibodies to SARS-35 CoV-2 nucleocapsid, spike antigen and spike components: RBD, S1, and 36 37 S2 target antigens. Shown are relative amounts of antibodies based upon Index values along with the 3 SD (Indeterminate threshold) and 6 SD cutoff 38 (Positive threshold) values. 39

40



Supplementary Figure 1



Supplementary Figure 2













16:20 21.25

26:30

erx.

0

1.10,1.15



















Supplementary Figure 3











IgG4_S2

Supplementary Figure 4

	Assay	MIA	MIA	MIA	MIA	MIA	VIDAS	Ortho	Abbott
	Antigens	N/RBD	N/RBD/Spike	Ν	RBD	Spike	RBD	S1	Ν
	Positive	1	2	0	1	2	1	0	0
	Indeterminate	5	6	2	3	2	0	0	0
Pro COVID	Negative	94	92	98	96	96	99	100	100
	Reactivity (%)	1	2	0	1	2	1	0	0
	Specificity (6SD*)(%)	99	98	100	99	98	99	100	100
	Specificity (3SD*)(%)	94	92	<u>98</u>	96	96			
Convolozoont	Positive	300	300	300	288	298	294	296	291
Convalescent	Indeterminate	0	0	0	9	0	0	0	0
(excluding MIA Indotorminatos	Negative	0	0	0	3	2	6	4	9
and Nogativos)	Sensitivity (6SD*) (%)	100	100	100	96	99	74	<i>98.7</i>	97
anu regatives)	Sensitivity (3SD*) (%)	100	100	100	99	99			
	Positive	352	390	344	319	388	328	361	295
Convalescent that	Indeterminate	32	0	28	42	0	0	0	0
Includes MIA	Negative	16	10	28	39	12	72	39	105
and Negatives	Sensitivity (6SD*) (%)	88	97.5	86	79.8	97	82	90.2	73.8
anu megatives	Sensitivity (3SD*) (%)	96	97.5	93	90.2	97			

Supplementary Table 1. Comparison of the NYS MIA with three commercial tests. 100 Pre-COVID serum specimens (*top panel*) and 400 serum specimens, collected from COVID-19 convalescent individuals 4-8 weeks post symptom onset, were screened using the NYS MIA (N plus RBD) and then re-tested using the NYS MIA (N plus RBD plus Spike) and three commercial tests on instrument platforms ((Biomerieux VIDAS, Ortho Vitros, Abbott Architect). One hundred specimens that screened as indeterminate or negative were excluded from the initial analysis (*middle panel*) and then included (*bottom panel*) to show test performance at the lower range of antibody concentration. All assays, including the MIA, specifically measured IgG antibodies. *Specificity and Sensitivity at different SD thresholds are for NYS MIA only.

Days from	Samples	RT- PCR	NY SARS Col	S-CoV MI mpared to	A Result as PCR	Sensitivity (95%CI)		
Unset	lested (IV)	result	Positive	Ind.	Negative			
IgM			·					
7 – 15	48	Pos	10	8	30	10/48 20.8% (11.73% - 34.26%)		
16 – 25	17	Pos	11	1	5	11/17 64.7% (41.30% - 82.69%)		
26 - 30	28	Pos	21	2	5	21/28 75% (56.64% - 87.32%)		
Total	93							
	T							
IgG								
7 – 15	48	Pos	16	5	27	16/48 33.3% (21.68% - 47.46%)		
16 - 25	17	Pos	12	1	4	12/17 70.6% (46.87% - 86.72)		
26-30	28	Pos	28	0	0	28/28 100% (87.94% - 100%)		
Total	93							
	•				· ·			
IgA								
7 – 15	48	Pos	28	5	15	28/48 58.3% (44.28% - 71.15%)		
16 - 25	17	Pos	12	0	5	12/17 70.6% (46.87% - 86.72%)		
26-30	28	Pos	21	2	5	21/28 75% (56.64% - 87.32%)		
Total	93							

Supplementary Table 2. Determination of MIA Sensitivity. A total of 93 serum specimens from individuals with SARS-CoV-2 infections, confirmed using RT-PCR, and reported symptom onset dates were assessed for antibodies of the indicated isotypes to the SARS-CoV-2 Nucleocapsid antigen and the RBD. A positive specimen is \geq 6 SD above the cutoff for either one of the target antigens; an indeterminate is \geq 3 SD above the cutoff for either or both of the target antigens; a negative is a sample with no reactivity to either target antigen. Sensitivities at different periods post symptom onset are shown on the right as the number of MIA positive specimens/total specimens tested.